WHAT: ABC2 Brain Cancer Research Lunch & Learn
WHEN: October 24, 2017, 11:30 AM – 1:30 PM
WHERE: The Case Foundation, 1717 Rhode Island Ave. NW, Suite 700, Wash., DC 20036
11:30 am – 11:50 am – “Next Gen Clinical Trials and Personalized Medicine”
Speaker: Max Wallace, CEO, ABC2
11:50am - 12:30pm – Lunch
12:30pm – 1:30pm – “INSIGhT Adaptive Clinical Trial for GBM” (For those unable to attend in person, a live webcast of the discussion is scheduled to begin at 12:30 pm EST on Facebook Live)
INSIGhT is the first-ever adaptive clinical trial in brain cancer. It matches targeted therapies with the patients most likely to benefit from them.
Dana Farber is leading a 10-institution consortium (Massachusetts General Hospital, The University of Alabama at Birmingham, Mayo Clinic, Columbia, Cleveland Clinic, MD Anderson, University of Pittsburgh, Utah/Huntsman, and University of Virginia) that will test multiple drugs in newly diagnosed patients in a rapidly adaptive environment.
As part of this, ABC² has joined with three pharmaceutical companies (Eli Lilly, Celgene and Puma Biotechnology) to fund the trial and ABC²'s Allele system does the front-end molecular analysis placing patients into the treatment arm most suitable for their individual tumor. Five institutions in the consortium have now begun recruiting patients and the others are soon to follow.
Speakers: Dr. Brian Alexander, INSIGhT Principal Investigator, Dana-Farber Cancer Institute and David Sandak, Senior Vice President, Strategy and Research, ABC2
Moderator: Max Wallace, CEO, ABC2
RSVP by October 16th, please contact us with any dietary restrictions for lunch
email@example.com | 202.419.3140
2017 Science Salon Series Sponsored by Genentech